|
|
Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights
J.E. Martin
,
S. Khalife-Hachem
,
T. Grinda
,
M. Kfoury
,
S. Garciaz
et al.
Journal articles
hal-03623367v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine
C. Bally
,
L. Ades
,
A. Renneville
,
M. Sebert
,
V. Eclache
et al.
Journal articles
hal-03653835v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial
C. Willekens
,
O. Blanchet
,
A. Renneville
,
P. Cornillet-Lefebvre
,
C. Pautas
et al.
Journal articles
inserm-01817446v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights
J.E. Martin
,
S. Khalife-Hachem
,
T. Grinda
,
M. Kfoury
,
S. Garciaz
et al.
Journal articles
hal-03376715v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion
Andrea Toma
,
O. Kosmider
,
S. Chevret
,
J. Delaunay
,
A. Stamatoullas
et al.
Journal articles
hal-01321412v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|